The first article in a two-part series, The Boston Consulting Group (BCG) explores the financial rationale driving the steady trend of M&A activity in the medical technology sector-as well as the business implications that result. Here, the authors examine the phenomenon of external players-industrial companies, conglomerates and others-acquiring companies and entering the medtech sector. The series draws on the valuation techniques, used by BCG's ValueScience Center, which combine proprietary discounted cash flow and relative valuation multiple models.
By Pete Lawyer and Rob Alford
This article is the first in a two-part series from The Boston Consulting Group (BCG) exploring the financial rationale driving...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
French biotech CellProthera is advancing to Phase III with its autologous CD34+ stem cell therapy that regenerates tissue after severe heart attacks.
Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
Abivax reflects on a transformative year marked by landmark clinical success and ambitious plans for the future.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
